Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress.
A natural plant compound reduced heart damage from chemotherapy in animal models and human cell studies, suggesting a potential protective strategy.
Oral intermittent fisetin (a natural senolytic) attenuated doxorubicin-induced premature vascular aging in mice by reducing cellular senescence and SASP, with improvements in endothelial function and arterial stiffness confirmed in parallel human cell studies. These findings support fisetin as a candidate therapeutic strategy for vascular toxicity in chemotherapy-treated cancer survivors.
What the study was
- Study design
- Controlled animal + in vitro study (mouse model + human aortic endothelial cells)
- Population
- Young adult mice treated with doxorubicin; parallel human aortic endothelial cell experiments
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Aging Cell
Why it surfaced
Mechanistically novel senolytic application (fisetin) to chemotherapy-induced vascular aging; primary data are animal/in vitro so score capped at 5.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.